Vaccinex, Inc. Overview
Pro stress-test →Vaccinex, Inc. is a clinical-stage biotechnology company developing pepinemab and ActivMAb® to target SEMA4D in neurodegenerative disease and cancer. The company believes SEMA4D plays a central role in neuroinflammation, astrocyte activation, and immune suppression in tumors. The company is pursuing development in Alzheimer's disease, Huntington's disease, and oncology indications.
Strategic Profile
Pro stress-test →The company's lead drug candidate is pepinemab, a humanized IgG4 monoclonal antibody designed to block SEMA4D. Vaccinex also intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations. The company operates with minimal capital and faces significant clinical and financial execution risks typical of early-stage biotech.
Competitive Landscape
Pro stress-test →Vaccinex competes in monoclonal antibody therapeutics for neurodegenerative diseases and cancer immunotherapy. Direct competitors include larger biotech/pharma companies developing anti-neuroinflammation approaches and checkpoint inhibitors (e.g., Biogen, Eli Lilly in Alzheimer's; Merck, Bristol Myers Squibb in cancer immunotherapy). The SEMA4D pathway is less crowded but pepinemab faces significant competition from established programs with larger clinical and commercial resources.
Industry Context
Vaccinex, Inc. operates in Monoclonal antibody therapeutics.
Key facts
Founded: 2001 · Headquarters: Rochester, New York · Employees: 37 · Revenue: $601K · Market cap: $2.8M